Adicet Bio, Inc. · NASDAQ:ACET

Adicet Bio — American College of Rheumatology (ACR) Annual Meeting 2024

15 slides from Adicet Bio's conference presentation, 2024

  1. Slide 1: ADI-001: An allogeneic CD20-targeted γδ CAR T cell therapy for autoimmune indications

    ADI-001: An allogeneic CD20-targeted γδ CAR T cell therapy with potential for improved tissue homing in autoimmune indications Monica Moreno, PhD Sr. Director, Translational Medicine Adicet Bio, Inc.

  2. Slide 2: Disclosure Statement

    Disclosure Statement • I have the following relevant financial relationship(s) to disclose:​​ Shareholder, Employee, Inventor on related patents: Adicet Therapeutics • In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechan

  3. Slide 3: ADI-001: A First Allogeneic CAR γδ T Cell Therapy

    ADI-001: A First Allogeneic CAR γδ T Cell Therapy ▪ ADI-001 is a first-in-class, allogeneic CAR γδ T cell therapy targeting the B-cell antigen CD20 with a novel human binder ▪ ADI-001 expresses MHC-independent γδ T cell receptors, thus lowering the risk of graft-versus- host disease (GvHD) without t

  4. Slide 4: ADI-001 is Highly Enriched for Vδ1 CAR+ T Cells That Possess a Favorable Phenotype

    ADI-001 is Highly Enriched for Vδ1 CAR+ T Cells That Possess a Favorable Phenotype Donor Selective αβ T Cell Final Leukapheresis Activation of Transduction Expansion Depletion Formulation Vδ1 T Cells Gated on CD27+ CD45RA+ cells CAR+ Vδ1 T cells CAR+ Vδ1 T cells Donor #1 Donor #2 Donor #3 Donor #1 T

  5. Slide 5: GLEAN: Phase 1 First in Human Study of ADI-001 in B-cell Non-Hodgkin's Lymphoma

    GLEAN: Phase 1 First in Human Study of ADI-001 (anti-CD20 gamma-delta 1 CAR T) in Patients with Previously Treated B-cell Non-Hodgkin’s Lymphoma Month 3, 6, 9 & 12 Response Screening Enrollment Day 1 - ADI-001 infusion Day 28 - response assessment assessment Lympho- Long-term Screening DLT evaluatio

  6. Slide 6: GLEAN Trial Case Study (1E8 cells): Clinical Response with No ICANS, CRS or GvHD

    GLEAN Trial Case Study (1E8 cells): Clinical Response Observed with No ICANS, CRS or GvHD • 62-year-old male • Mantle Cell Lymphoma • MIPI score 4, Stage IV • SPD 6,404 mm2 at baseline • 5 prior lines of therapy – Bendamustine + rituximab – Zanubrutinib – Bendamustine + obinutuzumab – Bendamustine +

  7. Slide 7: Assessment of CK and PD profile of ADI-001

    Assessment of CK and PD profile of ADI-001 Peripheral CK exposure by ddPCR and flow Multiple Pharmacodynamic assessment of CD19+ B cells by flow Levels of CK/PD support Ex vivo assessment of potent killing of patient-derived CD19+ B cells in Multiple Autoimmune Diseases Tissue CK/PD assessment of ex

  8. Slide 8: ADI-001's Cmax, D28 Persistence and AUC Consistent with Approved Autologous CD19 CAR T

    ADI-001’s Cmax, D28 Persistence and AUC Are Consistent with Values Reported for Approved Autologous CD19 CAR T1 ADI-001 CAR by Flow Cytometry ADI-001 CAR by ddPCR Absolute Count (Cells/uL), Mean+/-SEM Axi-cel Cmax: ~44 cell/uL2 3E7 Dose Level Mean Cmax Mean D28 1E8 Dose Level Dose Level CAR+ Vd1 CAR

  9. Slide 9: ADI-001 Cmax is Associated with Clinical Response in the GLEAN Study

    ADI-001 Cmax is Associated with Clinical Response in the GLEAN Study High Cmax observed irrespective of Expansion correlated with the degree degree of shared HLA alleles between of response ADI-001 and patients Cmax vs BOR Cmax vs degree of shared HLA alleles p* = 0.0217 10 6 1000000 10 5 Cmax (copi

  10. Slide 10: ADI-001: B-Cell Depletion Observed in GLEAN Trial Consistent with Autologous CD19 CAR T in SLE

    ADI-001: B-Cell Depletion Observed in GLEAN Trial Consistent with Autologous CD19 CAR T in SLE Academic Studies ∙ B-cell depletion data from ADI-001 trial in GLEAN study mirrored experience of autologous B-cell CD19 CAR T in SLE1,2 Depletion ∙ B-cell depletion via CD20 targeting validated by CD20-ta

  11. Slide 11: ADI-001 Exhibited Potent Killing of Patient-Derived CD19+ B Cells in Multiple Autoimmune Diseases

    ADI-001 Exhibited Potent Killing of Patient-Derived CD19+ B Cells in Multiple Autoimmune Diseases SLE Systemic Sclerosis Rheumatoid Arthritis (n=5 patient samples) (n=3 patient samples) (n=3 patient samples) 100% 100% 100% B Cell Viability (%) B Cell Viability (%) B Cell Viability (%) 80% 80% 80% 60

  12. Slide 12: ADI-001 Clinical Data Demonstrated Tissue Trafficking and CAR Activation

    ADI-001 Clinical Data Demonstrated Tissue Trafficking and CAR Activation ADI-001 Clinical Tissue Analyses ADI-001 Tissue Trafficking Exceeds Screening Biopsy Day 10 Post-Dose ADI-001 Data Reported for Axi-cel1 GrB Lymph Node ADI-001 Exposure Average CAR T per Million Cells DLBCL Lymph Node ADI-001 C

  13. Slide 13: Confirmation of CD19+ B Cell Depletion Within Tissues

    Confirmation of CD19+ B Cell Depletion Within Tissues MCL Patient Lymph Node Biopsies Intramuscular DLBCL Baseline Day 28 Post ADI-001 Screening Biopsy Day 10 Post ADI-001 Dose Blue : Nuclei Green: CD19+ cells Yellow: ADI-001 CAR Red: Granzyme B (T Cell Activation) 73y M, 2 prior lines (including SC

  14. Slide 14: γδ1 T Cells Preferentially Traffic to Solid Tissues

    γδ1 T Cells Preferentially Traffic to Solid Tissues: Addressing a Source of Resistance to Antibody Therapies lymph kidney3 lung4 skin5 bone breast7 liver8 GI9 node1,2 marrow 6 CD27+ tissue: >3X  issue/blood: tissue/blood: tissue/blood: tissue/blood: tissue/blood: tissue/blood: CD62L+ vs  9X 8X 4

  15. Slide 15: ADI-001: Multiple Levels of Evidence Support Potential in Autoimmune Disease

    ADI-001: Multiple Levels of Evidence Support Potential in Autoimmune Disease Robust CK and exposure in blood, consistent with autologous alpha-beta CAR T in autoimmune diseases Multiple Deep CD19+ B cell depletion below detectable levels in Levels of peripheral blood Evidence Supporting Exhibited ex

Adicet Bio — American College of Rheumatology (ACR) Annual Meeting 2024 on 6ix